Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Substance Use Disorder on the Inpatient Unit (Oct/Nov/Dec) | 2025

View Archived Issues

Learning Objectives, Substance Use Disorder on the Inpatient Unit, CATR, October/November/December 2025

July 1, 2025

After reading these articles, you should be able to…

Rapid Induction of Buprenorphine in Acute Care Settings

November 1, 2025

Jaewon Lee, MD, MPH and Noah Capurso, MD, MHS

New rapid induction strategies are allowing clinicians to start buprenorphine in acute care settings.

Phenobarbital for Inpatient Treatment of Alcohol Withdrawal

November 17, 2025

Mladen Nisavic, MD

Dr. Nisavic explains how phenobarbital offers advantages over benzodiazepines for alcohol withdrawal management, particularly in patients with benzodiazepine resistance. He details weight-based loading protocols, monitoring strategies, and the dual GABA/glutamate mechanism that may make phenobarbital superior for severe withdrawal cases.

Delirium Tremens: Recognition, Risk, and Practical Management

November 17, 2025

Craig Gunderson, MD

Dr. Gunderson provides expert guidance on recognizing and managing delirium tremens, challenging conventional wisdom about withdrawal timelines and offering practical approaches to risk stratification. He details his treatment approach for patients at high risk of developing withdrawal complications and discusses the differential diagnosis of delirium in hospitalized patients with alcohol use disorder.

Bipolar Disorder and Addiction: Untangling a Complex Overlap

November 1, 2025

Chris Aiken, MD

When bipolar disorder and substance use disorders co-occur patients can be difficult to diagnose and treat, particularly because they often present with mixed states rather than classic mood episodes. This article reviews evidence-based treatment approaches for specific substance combinations, including valproate for alcohol use, citicoline for stimulant use, and considerations for managing this complex dual diagnosis.

Methadone vs Buprenorphine: A Meta-Analysis

November 1, 2025

Monthe Kofos, DO

A massive meta-analysis of over one million participants provides the most comprehensive real-world comparison to date of methadone versus buprenorphine for opioid use disorder. While both medications are effective, methadone shows superior treatment retention at 3, 6, and 12 months, though the medications are largely comparable in other outcomes.

Varenicline Shows Promise for Vaping Cessation

November 1, 2025

Noah Capurso, MD, MHS

The first randomized controlled trial testing varenicline for e-cigarette cessation shows encouraging results. With 45% of participants achieving 7-day abstinence at week eight compared to 30% on placebo, this study provides preliminary evidence that varenicline may be effective for helping patients quit vaping, expanding its utility beyond traditional tobacco cessation.

CME Post-Test, Substance Use Disorder on the Inpatient Unit, CATR, October/November/December 2025

November 1, 2025

By successfully completing the test you will be awarded a certificate for 2 CME credits.

Psychiatry Practice Boosters, Fifth Edition (2026)
This fifth edition teaches you the key points of 66 of the most clinically relevant studies in...
READ MORE